EA017417B1 - КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ - Google Patents

КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ Download PDF

Info

Publication number
EA017417B1
EA017417B1 EA200870208A EA200870208A EA017417B1 EA 017417 B1 EA017417 B1 EA 017417B1 EA 200870208 A EA200870208 A EA 200870208A EA 200870208 A EA200870208 A EA 200870208A EA 017417 B1 EA017417 B1 EA 017417B1
Authority
EA
Eurasian Patent Office
Prior art keywords
zeg
tht
domain antibody
bie
sequence
Prior art date
Application number
EA200870208A
Other languages
English (en)
Russian (ru)
Other versions
EA200870208A1 (ru
Inventor
Энтони Джерард Дойл
Бенджамин П. Вулвен
Ян М. Томлинсон
Дженнифер А. Ли
Филип Энтони Дженнингз
Original Assignee
Сефалон Астралия Пти Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006900456A external-priority patent/AU2006900456A0/en
Application filed by Сефалон Астралия Пти Лтд. filed Critical Сефалон Астралия Пти Лтд.
Publication of EA200870208A1 publication Critical patent/EA200870208A1/ru
Publication of EA017417B1 publication Critical patent/EA017417B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
EA200870208A 2006-02-01 2007-02-01 КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ EA017417B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006900456A AU2006900456A0 (en) 2006-02-01 Domain antibody construct
US81750706P 2006-06-28 2006-06-28
PCT/AU2007/000085 WO2007087673A1 (en) 2006-02-01 2007-02-01 Domain antibody construct

Publications (2)

Publication Number Publication Date
EA200870208A1 EA200870208A1 (ru) 2009-02-27
EA017417B1 true EA017417B1 (ru) 2012-12-28

Family

ID=45220168

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870208A EA017417B1 (ru) 2006-02-01 2007-02-01 КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ

Country Status (12)

Country Link
US (2) US7846439B2 (enExample)
EP (1) EP1987064A4 (enExample)
JP (2) JP5259423B2 (enExample)
KR (1) KR20090039666A (enExample)
CN (2) CN103232540A (enExample)
AU (1) AU2007211829C9 (enExample)
BR (1) BRPI0707425A2 (enExample)
CA (1) CA2640661A1 (enExample)
EA (1) EA017417B1 (enExample)
MX (1) MX2008009792A (enExample)
NZ (1) NZ569988A (enExample)
WO (1) WO2007087673A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007019620A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
US20090286962A1 (en) * 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
NZ569988A (en) * 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
WO2008092209A1 (en) * 2007-02-01 2008-08-07 Arana Therapeutics Limited Protein construct with improved properties
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
EP2238165B1 (en) 2008-01-07 2017-07-05 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Anti-hiv domain antibodies and method of making and using same
KR20110044991A (ko) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＮＦ-α 길항제 다-표적 결합 단백질
US20110319597A1 (en) * 2008-08-14 2011-12-29 Caphalon Australia Pty. Ltd. Variant domain antibodies
CA2744055A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
EP2210902A1 (en) 2009-01-14 2010-07-28 TcL Pharma Recombinant monovalent antibodies
IT1394281B1 (it) * 2009-01-19 2012-06-06 Zardi Processo per la produzione di proteine di fusione polivalenti e polispecifiche utilizzando come struttura portante l'uteroglobina e prodotti cosi' ottenuti.
RU2595379C2 (ru) * 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
TWI507525B (zh) * 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
AU2012310328A1 (en) * 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof
CN104045715B (zh) * 2013-03-15 2018-05-01 兰州大学 二聚体化融合蛋白的制备及应用
CN108136012B (zh) * 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001974A1 (en) * 1987-09-04 1989-03-09 Celltech Limited Recombinant antibody
WO1989007142A1 (en) * 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO2002077029A2 (en) * 2000-11-07 2002-10-03 City Of Hope Cd19-specific redirected immune cells
US20030215427A1 (en) * 2001-04-11 2003-11-20 Michael Jensen CE7-specific redirected immune cells
US20030232971A1 (en) * 1989-08-07 2003-12-18 Rathjen Deborah Ann Tumour necrosis factor binding ligands

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0486526B2 (en) * 1989-08-07 2001-03-07 Peptech Limited Tumour necrosis factor binding ligands
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5994510A (en) 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998049286A2 (en) 1997-05-01 1998-11-05 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
IES80929B2 (en) 1997-11-26 1999-06-30 Donal Richard Mcgoey Filter with form-retaining stabilizing means
JP2002522063A (ja) * 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
GB9900298D0 (en) 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7235643B2 (en) 2000-11-07 2007-06-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with high affinity
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
WO2004085479A2 (en) 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
US20050136428A1 (en) 2003-06-27 2005-06-23 Roberto Crea Look-through mutagenesis
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
JP2007534305A (ja) 2003-11-07 2007-11-29 アムジェン インコーポレイテッド サル免疫グロブリン配列
WO2005052002A2 (en) 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
CA2558811A1 (en) 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
US6979473B2 (en) 2004-03-15 2005-12-27 Boston Scientific Scimed, Inc. Method for fine bore orifice spray coating of medical devices and pre-filming atomization
WO2006014477A1 (en) 2004-07-06 2006-02-09 Bioren, Inc. HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD
WO2006096653A2 (en) 2005-03-04 2006-09-14 Biogen Idec Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
CN101287762A (zh) 2005-08-15 2008-10-15 阿拉纳治疗有限公司 具有新世界灵长类构架区的经改造的抗体
WO2007019620A1 (en) 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
US20090286962A1 (en) 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
NZ569988A (en) 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EP2007808A4 (en) 2006-04-14 2010-07-21 Trubion Pharmaceuticals Inc BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
US20080139790A1 (en) 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
CA2682605A1 (en) 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
WO1989001974A1 (en) * 1987-09-04 1989-03-09 Celltech Limited Recombinant antibody
WO1989007142A1 (en) * 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US20030232971A1 (en) * 1989-08-07 2003-12-18 Rathjen Deborah Ann Tumour necrosis factor binding ligands
WO2002077029A2 (en) * 2000-11-07 2002-10-03 City Of Hope Cd19-specific redirected immune cells
US20030215427A1 (en) * 2001-04-11 2003-11-20 Michael Jensen CE7-specific redirected immune cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GenBank accession AAB37424 & Qi and Xiang (1995), "A genetically engineered single-gene-encoded anti-TAG72 chimeric antibody secreted from myeloma cells" Hum. Antibodies Hybridomas 6(4): 161-166 *
Muñoz E. et al. (1998), "The C1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3" International Immunology 10(2): 97-106, Fig. 1 and 2 *

Also Published As

Publication number Publication date
US20110044979A1 (en) 2011-02-24
JP5259423B2 (ja) 2013-08-07
EP1987064A1 (en) 2008-11-05
AU2007211829C9 (en) 2013-07-11
EP1987064A4 (en) 2010-04-07
AU2007211829B2 (en) 2012-11-08
JP2013059338A (ja) 2013-04-04
NZ569988A (en) 2011-09-30
WO2007087673A1 (en) 2007-08-09
BRPI0707425A2 (pt) 2011-05-03
JP2009525031A (ja) 2009-07-09
CN101400703A (zh) 2009-04-01
AU2007211829A1 (en) 2007-08-09
CN103232540A (zh) 2013-08-07
AU2007211829C1 (en) 2013-05-23
MX2008009792A (es) 2008-09-01
US20070202105A1 (en) 2007-08-30
CN101400703B (zh) 2013-05-08
AU2007211829C8 (en) 2013-06-27
US7846439B2 (en) 2010-12-07
CA2640661A1 (en) 2007-08-09
KR20090039666A (ko) 2009-04-22
EA200870208A1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
JP5259423B2 (ja) ドメイン抗体構築物
US12509501B2 (en) Polynucleotides encoding APOA-1 fusion polypeptides
JP2009525031A5 (enExample)
US11780916B2 (en) GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof
CN114641495A (zh) Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN110357959B (zh) Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US12221488B2 (en) APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01
JP2024514253A (ja) ヒトエンドセリン受容体に特異的に結合できる抗体及び糖尿病性腎症及び慢性腎疾患の治療におけるその応用
HK1130811A (en) Domain antibody construct
HK40015554A (en) Gipr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof
HK40016223B (en) Gcgr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof
NZ738963B2 (en) Apoa-1 fusion polypeptides and related compositions and methods
CN103796664A (zh) 抗备解素抗体和其应用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU